Silo Pharma Launches SP-26 Study For Chronic Pain And Fibromyalgia

Silo Pharma, Inc is a biopharmaceutical company in the developmental stage focusing on innovative drug delivery systems and treatments, including psychedelic therapies. The firm has announced the initiation of a pharmacokinetic (PK) and tolerability study. This study will be performed in collaboration with AmplifyBio, its contract research organization (CRO). The study aims to evaluate the pharmacokinetics of SP-26, a dissolvable ketamine-based injectable implant, in a minipig model. SP-26 is being developed as a self-administered, non-opioid treatment for chronic pain and fibromyalgia. 

Silo CEO Eric Weisblum, said, “So far this year we have conducted several studies of our SP-26 ketamine implants including analytical testing and small batch proof-of-concept extrusion trials, manufacturing and production evaluation, and sterilization and dissolution tests, with what we believe are encouraging results. The advancement of this program into animal studies is an important milestone achievement as we work to bring a safe and effective and to our knowledge, first-of-its-kind ketamine treatment for those living with chronic pain.”

Over a three-week period, the non-GLP study will examine how the extended-release ketamine hydrochloride implants are absorbed, distributed, metabolized, and excreted (ADME). The research will involve testing two different polymer formulations at multiple dose levels.

Jerry Hacker, EVP, and Chief Commercial Officer for AmplifyBio, commented, “AmplifyBio is honored to support Silo Pharma in this critical safety milestone for SP-26. We understand and take seriously the trust put in us to execute the PK study efficiently and with excellence.”